Corbus Pharmaceuticals Holdings, Inc. (CRBP) Income Statement
CRBP 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCRBP revenue and net income
CRBP profit margins
CRBP growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CRBP quarterly EPS vs estimates
Corbus Pharmaceuticals beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 11, 2026 (estimate $-1.45).
CRBP income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $881,705 | $3.9M | $36.1M | $4.8M | $2.4M | $1.9M |
| Cost of revenue | $233,000 | $600,000 | $31.2M | $1.5M | $1.6M | $98,267 | $89.6M | $48.6M | $26.0M | $15.4M |
| Gross profit | −$233,000 | −$600,000 | −$31.2M | −$1.5M | −$757,527 | $3.9M | −$53.5M | −$43.8M | −$23.6M | −$13.5M |
| Research & development | $70.1M | $32.2M | $31.2M | $16.1M | $36.4M | $98.3M | $89.6M | $48.6M | $26.0M | $15.4M |
| Sales, general & admin | $15.2M | $16.5M | $14.6M | $18.7M | $20.4M | $28.5M | $23.6M | $13.0M | $9.0M | $6.5M |
| Total operating expenses | $85.3M | $48.1M | $45.1M | $33.3M | $55.2M | $126.7M | $23.6M | $61.6M | $35.0M | $21.9M |
| Operating income | −$85.3M | −$48.7M | −$45.1M | −$34.8M | −$56.0M | −$122.8M | −$77.1M | −$56.7M | −$32.6M | −$20.0M |
| Interest income | $5.5M | $6.3M | $1.6M | — | — | — | $1.2M | $982,777 | $183,112 | $477 |
| Interest expense | $0 | $1.9M | $2.9M | $2.1M | $1.8M | $1.0M | $19,025 | $0 | $183,112 | $0 |
| Income before taxes | −$78.5M | −$40.2M | −$44.6M | −$42.3M | −$45.6M | −$111.3M | −$71.5M | −$55.7M | −$32.4M | −$20.0M |
| Income taxes | — | — | — | $13.5M | −$87,838 | $35,046 | −$2.3M | $1.1M | −$396,856 | $13,617 |
| Net income | −$78.5M | −$40.2M | −$44.6M | −$55.8M | −$45.6M | −$111.3M | −$71.5M | −$55.7M | −$32.4M | −$20.0M |
| EBITDA | −$78.3M | −$37.7M | −$40.1M | −$38.7M | −$42.2M | −$121.1M | −$75.9M | −$56.3M | −$32.3M | −$19.9M |
| EPS (diluted) | −$5.98 | −$3.66 | −$10.37 | −$10.41 | −$11.70 | −$44.40 | −$33.90 | −$29.40 | −$19.80 | −$14.70 |
| Gross margin | — | — | — | — | −85.9% | 100.0% | −147.9% | −908.1% | −967.1% | −707.6% |
| Operating margin | — | — | — | — | −6,350.1% | −3,119.2% | −213.3% | −1,176.8% | −1,334.4% | −1,045.6% |
| Net margin | — | — | — | — | −5,166.4% | −2,826.1% | −197.7% | −1,154.5% | −1,328.6% | −1,046.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $703,376 | $0 | $0 | $0 | $1.3M | $0 |
| Cost of revenue | $50,000 | $49,000 | $49,000 | — | $100,000 | $15.6M | $146,000 | $200,000 | $200,000 | $151,688 | $147,978 | $152,809 |
| Gross profit | −$50,000 | −$49,000 | −$49,000 | — | −$100,000 | −$15.6M | −$146,000 | −$200,000 | −$200,000 | −$151,688 | −$147,978 | −$152,809 |
| Research & development | $31.2M | $19.8M | $18.4M | $20.9M | $15.2M | $15.6M | $8.8M | $10.8M | $6.9M | $5.8M | $7.0M | $6.6M |
| Sales, general & admin | $5.0M | $4.5M | $3.6M | $3.6M | $4.0M | $4.1M | $3.8M | $4.7M | $4.1M | $4.0M | $3.1M | $2.9M |
| Total operating expenses | $36.2M | $24.3M | $22.0M | $24.4M | $19.1M | $4.1M | $12.5M | $15.5M | $10.8M | $9.6M | $10.0M | $9.5M |
| Operating income | −$36.2M | −$24.3M | −$22.0M | −$24.4M | −$19.2M | −$19.8M | −$12.6M | −$15.5M | −$11.0M | −$9.6M | −$10.1M | −$9.5M |
| Interest income | $1.2M | $1.4M | $1.4M | $1.1M | $1.3M | $1.7M | $3.6M | $1.2M | $906,000 | $1.0M | — | $217,000 |
| Interest expense | — | — | $0 | $0 | $0 | $0 | $661,985 | $381,000 | $652,000 | $177,015 | $707,010 | $763,356 |
| Income before taxes | −$35.0M | −$23.0M | −$20.6M | −$23.3M | −$17.7M | −$17.0M | −$9.5M | −$13.8M | −$10.0M | −$6.9M | −$8.0M | −$10.1M |
| Income taxes | — | — | — | — | — | — | — | — | — | $2 | $1 | $828,092 |
| Net income | −$35.0M | −$23.0M | −$20.6M | −$23.3M | −$17.7M | −$17.0M | −$9.5M | −$13.8M | −$10.0M | −$6.9M | −$8.0M | −$10.1M |
| EBITDA | −$35.0M | −$22.9M | −$20.5M | −$23.3M | −$17.6M | −$18.6M | −$9.4M | −$13.2M | −$9.1M | −$5.9M | −$7.2M | −$8.9M |
| EPS (diluted) | −$1.81 | −$1.23 | −$1.25 | −$1.90 | −$1.44 | −$1.39 | −$0.78 | −$1.15 | −$0.90 | −$0.83 | −$1.81 | −$2.27 |
| Gross margin | — | — | — | — | — | — | −20.8% | — | — | — | −11.0% | — |
| Operating margin | — | — | — | — | — | — | −1,792.1% | — | — | — | −748.5% | — |
| Net margin | — | — | — | — | — | — | −1,354.9% | — | — | — | −594.3% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CRBP's financial statements (latest annual report filed March 9, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CRBP financial results
Corbus Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $78.5 million. Diluted earnings per share came to −$5.98.
See the CRBP stock overview for the latest quote and news, or the CRBP chart for price history and technical indicators.
CRBP income statement FAQ
Does Corbus Pharmaceuticals have revenue?
Corbus Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Corbus Pharmaceuticals profitable?
No. Corbus Pharmaceuticals reported a net loss of $78.5 million in fiscal 2025.
How much does Corbus Pharmaceuticals spend on research and development?
Corbus Pharmaceuticals spent $70.1 million on research and development in fiscal 2025.
What are Corbus Pharmaceuticals's earnings per share?
Corbus Pharmaceuticals earned $-5.98 per diluted share in fiscal 2025, compared with $-3.66 a year earlier.
When will Corbus Pharmaceuticals report its next earnings?
Corbus Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Corbus Pharmaceuticals's fiscal year end?
Corbus Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 9, 2026.